Panel: Are innovation and Excipients Mutually Exclusive?

- How non-accidental excipients are at the crossroads between regulation, return on investment and innovation

- Why advanced formulations require excipients designed for purpose and why the safety requirements are not a barrier to innovation

- Are there data gaps in the safety (pharmacovigilance) knowledge of excipients?

- Why we need a positive (and negative) list of excipients and their approved routes of administration